Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-04-12 08:53:13 ET More on Adaptimmune Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune: Drug Approval Now Imminent? FDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4 Seeking Alpha’s Quant Rating...
2024-04-11 18:33:21 ET Shares of Swiss pharmaceuticals giant Roche Holdings (OTC: RHHBY) stock popped 2.5% in early trading Thursday before giving back about half of its gains. Roche announced this morning that the U.S. Food and Drug Administration has awarded the "Breakthrough ...
2024-04-11 06:20:37 ET Roche ( OTCQX:RHHBY ) and partner Eli Lilly ( NYSE: LLY ) have received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for their Elecsys pTau217 assay to support early diagnosis of Alzheimer's disease.... Read th...
2024-04-10 06:50:33 ET Summary Halozyme's ENHANZE technology drives growth, with Q4 2023 revenue up 27% YoY, projecting $915-$985 million in 2024. Key revenue from royalties, notably Darzalex Faspro, with a healthy financial state highlighted by a strong current ratio and stock re...
2024-04-10 05:49:03 ET Roche ( OTCQX:RHHBY ) has obtained CE Mark for its pre-diluted VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx test.... Read the full article on Seeking Alpha For further details see: Roche companion diagnostic test wins CE Mark to i...
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU PR Newswire Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2. 1 Patients with HE...
2024-04-09 11:30:10 ET Summary Today, we take a look at Novo Nordisk A/S, whose growth is being powered by Wegovy and Ozempic. The GLP-1 market is projected by some to grow to $100 billion by 2030 and Novo Nordisk is currently the preeminent player in this burgeoning space. Ho...
2024-04-09 11:00:51 ET More on Syros Pharmaceuticals Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript Syros Pharmaceuticals: Rising Despite Dilution, A Must Look Syros Pharmaceuticals GAAP EPS of -$2.18 misses by $1.04, revenue of $0.4M misses by $...
2024-04-07 13:31:00 ET More on Merck, SPDR S&P Biotech ETF, etc. Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade) Merck: Better Times Ahead On Approvals And Outlook Merck's Future Brightens With Winrevair's Blockbuster Potential ...
2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...